ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
about
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selectionc-Met as a Target for Personalized TherapyMET inhibitors in combination with other therapies in non-small cell lung cancerThe role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsDiscoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discoveryResearch Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung CancerCombination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelA Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases: DISCOVERY OF ATP-INDEPENDENT INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTORRole of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaProfile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to dateClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionHepatocellular carcinoma: Where there is unmet needA simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assaysAlternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancerThe oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitorRANK-mediated signaling network and cancer metastasis.Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentPotential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.Efficacy of c-Met inhibitor for advanced prostate cancer.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapiesBiomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASDetection of estrogen-independent growth-stimulating activity in breast cancer tissues: implication for tumor aggressivenessSmall-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesMET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.Development of c-MET pathway inhibitors.The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer ModelsMolecular targeting to treat gastric cancer.Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis.Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsThe Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastomaReceptor-tyrosine-kinase-targeted therapies for head and neck cancer.RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
P2860
Q24608143-4E7D0D7F-C2DB-4E63-ADF3-673FDB6B0AA8Q26738860-AC211478-7F2A-480F-A968-E61C3A58699FQ26775483-17525680-F933-4EA2-9D56-5F3B5689A14FQ26823203-872E6C77-E483-4814-819A-B37AC04E4620Q26823903-D6D4C239-3A35-4896-A51F-11E27A83ACDAQ26853215-9A8B2659-B664-4022-A14A-819D502AB0E0Q27006349-02D7626A-7394-4296-9801-1C973378EC46Q27302940-BF676D21-862C-4668-A20D-640EFD6F952FQ27667388-E4474B56-F84C-41C0-B6F3-50118443604BQ28070762-115CAACB-073A-4213-9FCE-E2FFA3A297A6Q28071589-645B2F93-49BF-49C1-899D-439AA3867ED4Q28074834-1E013456-A39B-454E-A905-05FF1430BB5DQ28084046-4BFD9900-0CA6-47AC-A031-8D42276A2C87Q28488243-5CF3FBDE-E8CD-4B66-8C4B-6FC9396334DEQ28534819-A620439C-523E-4A49-946A-019A7E936376Q28821187-F1F74489-30C3-49A3-AF4C-73A375C6F522Q30371052-C567752F-BE1B-4876-A447-A5AC5815B27DQ33161299-F580A722-147D-4720-86D6-F38D7355A831Q33162379-D9E24774-0884-4110-A8CB-B8C5F1B604AFQ33401272-98EB8D67-B273-484E-8397-6A4614743E0CQ33414632-1EE4AA3A-ABF2-4326-BE62-DA99BCC34D53Q33607965-D0E61FF6-6D44-4353-96DF-73AA133E8C16Q33652455-4990B3EF-A554-4598-A80C-F3642F5C1793Q33718726-CAE843DA-0F4C-4A33-BB17-EBB7A88DDB4CQ33769429-B367E814-69E3-44DC-B5FB-B458DB03338DQ33769437-AA3BCD94-BFC2-4339-BDB5-27E96CE21EC0Q33880542-F4CD7184-16F2-4247-8630-CC156F5193F8Q33895113-D9CFF5E8-C698-497E-BDF5-3CEF6EA8A918Q34023414-3251ADB7-9538-42E5-B609-8981FA3E0BE1Q34115972-BBE25CBE-662C-4FC3-AF83-517BF7B37B3FQ34158454-764440EF-45DE-4048-A8E5-D51A03A7849CQ34182679-2B03DE55-CB55-4D5B-B037-BA7B3F2CDDC8Q34198905-8E211654-4D32-4D7B-B235-CE9AB94EDEF7Q34309954-0A15D81A-8836-48E7-9BFB-B662F7E892D3Q34326593-D8B69DC5-193D-47BA-98BA-4D11EE4D19EBQ34758473-FE59A761-C732-49A0-9488-253E5D2D8F33Q34964958-ADA42B99-5F2E-4B4D-8A76-DF26F60CA398Q34996463-7FB08A83-47DF-4635-8B91-9F6A318EC4A6Q35102025-A4DA44FC-23D1-4EC7-9F5A-646AB45D1143Q35146597-006F7A54-8538-47FD-9AB1-630CE390B3B3
P2860
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
ARQ 197, a novel and selective ...... inase with antitumor activity.
@en
ARQ 197, a novel and selective ...... inase with antitumor activity.
@nl
type
label
ARQ 197, a novel and selective ...... inase with antitumor activity.
@en
ARQ 197, a novel and selective ...... inase with antitumor activity.
@nl
prefLabel
ARQ 197, a novel and selective ...... inase with antitumor activity.
@en
ARQ 197, a novel and selective ...... inase with antitumor activity.
@nl
P2093
P1476
ARQ 197, a novel and selective ...... kinase with antitumor activity
@en
P2093
Chang-Rung Chen
Chiang J Li
David S Leggett
Dennis S France
Jason Hill
Magdi M Moussa
Mark A Ashwell
Neru Munshi
P304
P356
10.1158/1535-7163.MCT-09-1173
P577
2010-05-18T00:00:00Z